NCT03172754View on ClinicalTrials.gov

Study of Nivolumab and Axitinib in Patients With Advanced Renal Cell Carcinoma

PHASE1/PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

98

Participants

Timeline

Start Date

June 12, 2017

Primary Completion Date

April 6, 2025

Study Completion Date

October 6, 2025

Conditions
Renal Cell Carcinoma
Interventions
DRUG

Nivolumab

PD-1 inhibitor

DRUG

Axitinib

Tyrosine kinase inhibitor

Trial Locations (4)

10021

Cornell, New York

12206

US Oncology and Hematology, Albany

19111

Fox Chase Cancer Center, Philadelphia

21231

Johns Hopkins, Baltimore

All Listed Sponsors
lead

Fox Chase Cancer Center

OTHER

NCT03172754 - Study of Nivolumab and Axitinib in Patients With Advanced Renal Cell Carcinoma | Biotech Hunter | Biotech Hunter